세계의 기관염 치료 시장 보고서(2025년)
Tracheitis Treatment Global Market Report 2025
상품코드 : 1825567
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

기관염 치료 시장 규모는 향후 수년간 안정된 성장이 전망됩니다. 2029년에는 CAGR 3.8%로 69억 달러로 성장합니다. 예측 기간의 성장은 항균제 내성, 예방접종 프로그램, 맞춤형 의료, 기후 변화에 기인합니다. 예측 기간의 주요 동향으로는 진단의 발전, 표적 치료, 가상 건강 상담, 다학제적 치료, 환자 교육 및 예방, 바이오마커 연구 등이 있습니다.

향후 5년간 3.8%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 일본과 독일에서 조달하는 소아 기관지경 및 분무 항생제 용액의 비용을 상승시켜 중요한 기도 중재를 지연시키고 소아 중환자실 지출을 증가시킴으로써 미국을 방해할 것으로 예측됩니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

흡연율 증가는 향후 기관지염 치료제 시장 확대의 원동력이 될 것으로 예측됩니다. 흡연은 식물, 특히 담배를 태울 때 발생하는 연기를 들이마시거나 내뿜는 것으로 기관지염, 심장병, 뇌졸중, 암 등 많은 건강 위험과 관련이 있습니다. 흡연은 기관 내벽을 손상시켜 감염에 취약하게 만듭니다. 기관지염에 걸리면 기침, 쉰 목소리, 호흡곤란 등의 증상이 나타납니다. 예를 들어 2022년 7월 캐나다 통계청 데이터에 따르면 2021년 6월에 비해 담배 생산량이 5.8% 증가했습니다. 또한 담배 총 판매량은 2022년 5월 대비 1.3% 증가하여 2022년 6월에는 14억 개비에 달했습니다. 또한 미국 정부 기관인 질병통제예방센터에 따르면 2023년 5월 현재 미국에서는 약 2,830만 명의 성인이 담배를 피우고 있으며, 미국에서는 308만 명의 중고등학생이 최소 1개 이상의 담배 제품을 사용하고 있는 것으로 추정됩니다. 그 결과, 흡연의 확산이 기관지염 치료 시장 성장의 원동력이 되고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Tracheitis is characterized by infection and inflammation of the trachea, with bacterial infections, particularly Staphylococcus aureus, being the most common causative agents. Tracheitis treatment aims to effectively alleviate symptoms, slow the progression of the disease, and avert potential complications. This therapeutic approach typically entails a prompt evaluation to assess any airway compromise, the maintenance of airway integrity, and the administration of antibiotics.

The primary bacterial strains encompassed within tracheitis treatment protocols include Streptococcus pneumoniae, Staphylococcus aureus, and other relevant pathogens. Streptococcus pneumoniae pertains to a gram-positive bacterial strain capable of causing pneumococcal disease. Tracheitis presents in various clinical forms, such as tracheobronchitis, bacterial croup, and laryngotracheobronchitis, all of which can be effectively managed through diverse treatment modalities. These treatments encompass procedures like endotracheal intubation, antibiotic therapies, and other pertinent interventions. Multiple healthcare settings, including hospitals and specialized clinics, serve as essential venues for delivering these treatments.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The tracheitis treatment market research report is one of a series of new reports from The Business Research Company that provides tracheitis treatment market statistics, including tracheitis treatment industry global market size, regional shares, competitors with a tracheitis treatment market share, detailed tracheitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the tracheitis treatment industry. This tracheitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tracheitis treatment market size has grown steadily in recent years. It will grow from $5.79 billion in 2024 to $5.94 billion in 2025 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to bacterial infections, growing viral infections, increasing smoking, growing pollution.

The tracheitis treatment market size is expected to see steady growth in the next few years. It will grow to $6.9 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to antimicrobial resistance, immunization programs, personalized medicine, climate change. Major trends in the forecast period include diagnostic advancements, targeted therapies, virtual health consultations, multidisciplinary care, patient education and prevention, research in biomarkers.

The forecast of 3.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of pediatric bronchoscopes and nebulized antibiotic solutions sourced from Japan and Germany, thereby delaying critical airway interventions and elevating pediatric ICU expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of smoking is expected to be a driving force behind the future expansion of the tracheitis treatment market. Smoking, which involves the inhalation and exhalation of smoke generated from the burning of plant materials, most commonly tobacco, is associated with a multitude of health risks, including tracheitis, heart disease, stroke, and cancer. Smoking inflicts damage to the tracheal lining, rendering it more vulnerable to infections. Tracheitis, in turn, results in symptoms such as persistent coughing, hoarseness, and breathing difficulties. For instance, data from Statistics Canada in July 2022 revealed a 5.8% increase in cigarette production compared to June 2021. Furthermore, the total volume of cigarettes sold rose by 1.3% from May 2022, reaching a total of 1.4 billion in June 2022. In addition, as of May 2023, according to the Centers for Disease Control and Prevention, a U.S.-based government agency, approximately 28.3 million adults in the United States continue to smoke cigarettes, while an estimated 3.08 million middle and high school students in the U.S. use at least one tobacco product. Consequently, the escalating prevalence of smoking is a driving factor in the growth of the tracheitis treatment market.

The escalating incidence of chronic obstructive pulmonary disease (COPD) is anticipated to be a driving force behind the expansion of the tracheitis treatment market. Chronic Obstructive Pulmonary Disease (COPD) is a persistent and progressive respiratory ailment marked by ongoing airflow limitation in the lungs. Tracheitis treatment offers several advantages to individuals grappling with COPD, including a reduced risk of respiratory infections, enhanced lung function, relief from symptoms, and the prevention of exacerbations. For example, data from a report published by The Scottish Public Health Observatory (ScotPHO) in March 2023, revealed an uptick in COPD rates between 2021 and 2022. During this period, rates for males rose from 83.2 to 97.6 per 100,000 individuals, while female rates increased from 72.6 to 97.3. Consequently, the surging prevalence of chronic obstructive pulmonary disease (COPD) is a driving factor in the growth of the tracheitis treatment market.

Major companies operating in the tracheitis treatment market are focusing on developing innovative solutions, such as novel antibiotics, to address resistant infections and improve patient outcomes. Novel antibiotics are newly developed drugs that target bacterial infections in ways that existing treatments may not, offering hope against drug-resistant strains. For example, in September 2024, Wockhardt Ltd., an India-based pharmaceutical company, launched a novel antibiotic, WCK 5222, branded as Zaynich. This antibiotic is designed to combat infections caused by multi-drug-resistant (MDR) bacteria, a growing concern in the treatment of respiratory infections like tracheitis. The drug is priced at 80% less than its US counterpart, making it more accessible to patients in India and addressing the urgent need for effective treatments in the region. This move highlights the importance of affordable and innovative antibiotic solutions in managing respiratory diseases, including tracheitis.

In October 2022, Switzerland-based biotechnology company Sandoz made a strategic move by acquiring GSK plc's cephalosporin antibiotics business, a transaction of undisclosed value. This acquisition marks a significant expansion of Sandoz's antibiotics portfolio, reinforcing its position within the global antibiotic market. By securing the rights to three renowned brands-Zinnat, Zinacef, and Fortum-in more than 100 markets, Sandoz further cements its status as a market leader in the realm of antibiotics. Notably, cephalosporins, a class of antibiotics, play a crucial role in effectively treating tracheitis stemming from bacterial infections. GSK PLC, a UK-based pharmaceutical company, has been a key player in providing antibiotic medications tailored for tracheitis treatment. This strategic acquisition bolsters Sandoz's commitment to enhancing its tracheitis treatment offerings.

Major companies operating in the tracheitis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck & Co., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Sanofi S.A., Takeda Pharmaceutical Company, Medtronic PLC, Eli Lilly and Company, Cipla Limited, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries, Astellas Pharma, Fresenius Kabi, Sun Pharmaceutical Industries, Hikma Pharmaceuticals PLC, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals, SAVAL Pharmaceuticals S.A., Melinta Therapeutics Inc., Genom Biotech Pvt. Ltd.

North America was the largest region in the tracheitis treatment market in 2024. The regions covered in tracheitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tracheitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tracheitis treatment market consists of revenues earned by entities by providing laryngoscopy, respiratory therapy, physical therapy and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The tracheitis treatment market also includes sales of bronchodilators, steroids, humidifiers and pain relievers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tracheitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tracheitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for tracheitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tracheitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Tracheitis Treatment Market Characteristics

3. Tracheitis Treatment Market Trends And Strategies

4. Tracheitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tracheitis Treatment Growth Analysis And Strategic Analysis Framework

6. Tracheitis Treatment Market Segmentation

7. Tracheitis Treatment Market Regional And Country Analysis

8. Asia-Pacific Tracheitis Treatment Market

9. China Tracheitis Treatment Market

10. India Tracheitis Treatment Market

11. Japan Tracheitis Treatment Market

12. Australia Tracheitis Treatment Market

13. Indonesia Tracheitis Treatment Market

14. South Korea Tracheitis Treatment Market

15. Western Europe Tracheitis Treatment Market

16. UK Tracheitis Treatment Market

17. Germany Tracheitis Treatment Market

18. France Tracheitis Treatment Market

19. Italy Tracheitis Treatment Market

20. Spain Tracheitis Treatment Market

21. Eastern Europe Tracheitis Treatment Market

22. Russia Tracheitis Treatment Market

23. North America Tracheitis Treatment Market

24. USA Tracheitis Treatment Market

25. Canada Tracheitis Treatment Market

26. South America Tracheitis Treatment Market

27. Brazil Tracheitis Treatment Market

28. Middle East Tracheitis Treatment Market

29. Africa Tracheitis Treatment Market

30. Tracheitis Treatment Market Competitive Landscape And Company Profiles

31. Tracheitis Treatment Market Other Major And Innovative Companies

32. Global Tracheitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tracheitis Treatment Market

34. Recent Developments In The Tracheitis Treatment Market

35. Tracheitis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기